the CHMP has dealt a severe blow to the company's hopes of boosting Folotyn's sales.

Allos is looking to get Folotyn approved in the EU for treating patients suffering from peripheral T-cell lymphoma whose disease progressed after at least one prior systemic therapy.

We note that Folotyn is already available in the US for the PTCL indication. The drug received accelerated approval from the Food and Drug Administration in September 2009.

We note that Allos inked a co-development and commercialization deal with Mundipharma in May 2011 for Folotyn. Per the terms of the deal, the sole responsibility for commercializing the drug in the US and Canada lies with Allos.

We note that Folotyn is already available in the US for the PTCL indication. The drug received accelerated approval from the Food and Drug Administration in September 2009.


Allos is looking to get Folotyn approved in the EU for treating patients suffering from peripheral T-cell lymphoma whose disease progressed after at least one prior systemic therapy.

We remind investors that Allos sought a re-examination of the negative opinion issued by the CHMP. By sticking to its negative opinion, the CHMP has dealt a severe blow to the company's hopes of boosting Folotyn's sales.

We remind investors that Allos sought a re-examination of the negative opinion issued by the CHMP. By sticking to its negative opinion, the CHMP has dealt a severe blow to the company's hopes of boosting Folotyn's sales.

We remind investors that Allos sought a re-examination of the negative opinion issued by the CHMP. By sticking to its negative opinion, the CHMP has dealt a severe blow to the company's hopes of boosting Folotyn's sales.

Mundipharma is responsible for commercializing Folotyn in the rest of the world. Mundipharma has already filed marketing applications in countries like Australia, South Korea and Switzerland.

Mundipharma is responsible for commercializing Folotyn in the rest of the world. Mundipharma has already filed marketing applications in countries like Australia, South Korea and Switzerland. custom jerseysAllos is looking to get Folotyn approved in the EU for treating patients suffering from peripheral T-cell lymphoma whose disease progressed after at least one prior systemic therapy.

We note that Allos inked a co-development and commercialization deal with Mundipharma in May 2011 for Folotyn. Per the terms of the deal, the sole responsibility for commercializing the drug in the US and Canada lies with Allos. custom personality jerseys
Mundipharma is responsible for commercializing Folotyn in the rest of the world. Mundipharma has already filed marketing applications in countries like Australia, South Korea and Switzerland.

We note that Allos inked a co-development and commercialization deal with Mundipharma in May 2011 for Folotyn. Per the terms of the deal,Nick Barnett Jersey, the sole responsibility for commercializing the drug in the US and Canada lies with Allos.

We note that Folotyn is already available in the US for the PTCL indication. The drug received accelerated approval from the Food and Drug Administration in September 2009.